The extended followup if the trial (median 4.1 year) revealed that patients randomized to chronic insulin treatment (group 1) has a significantly higher (4.4 versus 2.0%) cumulative cancer-related mortality than the other two groups [60]. This evidence concerns the gene INS and cancer.